Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results

aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the Top 10 Stocks Under $10 That Could Triple. On August 22, Jefferies increased its price target for aTyr Pharma, Inc. (NASDAQ:ATYR) from $9 to $17 while keeping a Buy rating.

This decision comes ahead of the Phase 3 trial results for aTyr Pharma, Inc.’s (NASDAQ:ATYR) lead candidate, efzofitimod. The company plans to release topline data from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis in mid-September 2025.

Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results

Jefferies outlined three possible outcomes for the trial results. The firm sees a 37% chance of a strong positive result, showing a drop of more than 3mg in daily oral corticosteroid dose. According to the firm, this could cause aTyr Pharma, Inc.’s (NASDAQ:ATYR) stock price to rise by 3 to 5 times.

The firm sees a 23% chance for base case results, with a 1.87 to 3mg reduction, which could push the stock price 1 to 3 times higher. Jefferies assigned a 40% probability to negative results from the study, which could see the stock price fall by up to 75%.

Jefferies pointed out that there is a big unmet need for treatments for pulmonary sarcoidosis, which does not have any approved therapies yet. The firm noted that early Phase 1 and 2 proof-of-concept data showed encouraging signs, offering hope for positive outcomes in the Phase 3 trial.

aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on using evolutionary intelligence and tRNA synthetase biology to develop new treatments for diseases involving fibrosis and inflammation.

While we acknowledge the potential of ATYR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATYR and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Hot Mid Cap Stocks to Buy Now and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.